Complement-targeted therapeutics
Article Abstract:
The current therapeutic strategies are discussed by focusing on complement-targeted drug candidates that are in clinical trials or in late preclinical development. The approval of eculizumab has validated the complement system as therapeutic target and it might facilitate clinical development of other potential drug candidates.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Weighing the outcomes
Article Abstract:
The issue of increasing evaluation of their overall healthcare value by the healthcare payers, its subsequent results and the steps to be taken by the drug manufacturers are discussed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The biotech company view. Becoming an American company: A holistic approach to decision making. Sidney Wolfe
- Abstracts: Research issues in building brand equity and global brands in the pc market. part 2 Involving stakeholders in developing corporate brands: the communication dimension
- Abstracts: Pioneering advantage and product-country image: evidence from an exploratory study in China. Market-based organizational learning-theoretical reflections and conceptual insights
- Abstracts: Effect of stiffness and movement speed on selected dynamic torque characteristic of hydraulic-actuation joystick controls for heavy vehicles
- Abstracts: Monoclonal expand into neural disorders. Ann Arbor community rallies in wake of Pfizer shutdown. Incretin mimetics vie for slice of type 2 diabetes market